A Phase 2 interventional study of ONO-2808 and Placebo in Multiple System Atrophy (MSA), sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 35 sites in 2 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Multiple System Atrophy with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Multiple System Atrophy · United States.
Among the 90 studies in Multiple System Atrophy with a site in United States, this one is the 17th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2023, is one of 17 in phase 2, reaches primary completion later than 1 of the 31 other live ones, and was the 74th registered.
207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.
Browse Multiple System Atrophy studies →21 of the 90 studies in Multiple System Atrophy with a site in United States are open now. Recruiting first, the newest first:
Prabesh Kanel · Sites in United States
Ages 45+
MODAG GmbH · Sites in United States
Ages 18–60 · Healthy volunteers
MODAG GmbH · Sites in United States
Ages 50–80 · Healthy volunteers
Teva Branded Pharmaceutical Products R&D LLC · Sites in United States, France, Germany and 4 more countries
Ages 30+
Tiziana Life Sciences LTD · Sites in United States
Ages 30–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 20 · Phase 3 7 · Phase 4 2
First in 1995; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 41 across 134 interventional studies indexed under Multiple System Atrophy.
Median enrollment 35 across the 57 interventional studies, 184 across the 31 observational. Of the 53 that completed or were terminated, 19 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 90 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ono Pharmaceutical Co., Ltd., one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Ono Pharmaceutical Co. Ltd has 2 studies filed under Multiple System Atrophy — fewer than ten, so there is no comparison to draw.
19 of the studies in Multiple System Atrophy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT03042988Vanderbilt University Medical CenterOvernight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension | 2026-11-30 |
| NCT05167721Mayo ClinicRandomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy | 2026-12 |
| NCT02726711Vanderbilt UniversityReduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic | 2026-12 |
| NCT03312556Vanderbilt University Medical CenterTreatment of Supine Hypertension in Autonomic Failure (CPAP) | 2026-12-21 |
Add all 19 to your calendar (.ics) → With an account.
Among the 90 studies in Multiple System Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
This study will consist of a core part, an extension part, and an additional extension part. The purpose of the core part is to evaluate 3 doses of ONO-2808 compared to placebo in MSA patients, including: 1) safety and tolerability, 2) pharmacokinetics, and 3) changes in clinical outcome assessments (COA) and biomarkers considered to be related to the pharmacodynamics and potential efficacy of ONO-2808. The purpose of the extension part and the additional extension part is to evaluate 3 doses of ONO-2808 in MSA patients, including: 1) safety and tolerability and 2) changes in COAs and biomarkers considered to be related to the pharmacodynamics and potential efficacy of ONO-2808.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients at the early stages of the disease, defined as a maximum of 5 years since the onset of one of the following symptoms associated with MSA:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ONO-2808
Drug: Placebo
Oral administration of ONO-2808 at low, middle or high doses once daily for 24 weeks in the core part, for a total of 80 weeks including the extension part, and for up to an additional 72 weeks in the additional extension part
Oral administration of placebo once daily for 24 weeks in the core part and for a total of 32 weeks including the extension part; Transition to low-dose of ONO-2808 for remainder of the extension part until week 80 and for up to an additional 72 weeks in the additional extension part
Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment. A TEAE was considered study treatment-related if there was a reasonable causal relationship between study intervention administration and the TEAE. A serious adverse event (SAE) was an event that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in significant disability/incapacity, was a congenital anomaly/birth defect, or was considered an important medical event.
Time frame: From screening up to follow-up for the core part (up to Week 28)
Incidence of TEAEs by Highest Severity
A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment.
Time frame: From screening up to follow-up for the core part (up to Week 28)
Incidence of Study Treatment-related TEAEs by Highest Severity
A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment. A TEAE was considered study treatment-related if there was a reasonable causal relationship between study intervention administration and the TEAE.
Time frame: From screening up to follow-up for the core part (up to Week 28)
Plasma Concentration of ONO-2808
Descriptive summary statistics were calculated for ONO-2808 plasma concentrations, by dose level and time point.
Time frame: Week 2, Week 8, Week 12, and Week 24
| Milestone | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High |
|---|---|---|---|---|
| Started | 23 | 23 | 23 | 23 |
| Completed | 19 | 18 | 17 | 16 |
| Not completed | 4 | 5 | 6 | 7 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 2 | 3 | 5 |
| Withdrew: Death | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 | 1 | 1 |
| Withdrew: Non-complicance with study drug | 0 | 1 | 0 | 0 |
| Withdrew: Other | 2 | 1 | 1 | 0 |
| Milestone | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment. A TEAE was considered study treatment-related if there was a reasonable causal relationship between study intervention administration and the TEAE. A serious adverse event (SAE) was an event that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in significant disability/incapacity, was a congenital anomaly/birth defect, or was considered an important medical event.
| Participants | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High |
|---|---|---|---|---|
| Incidence of TEAEs | 21 | 22 | 21 | 21 |
| Incidence of study treatment-related TEAEs | 7 | 5 | 6 | 11 |
| Incidence of TEAEs leading to withdrawal of study treatment | 1 | 2 | 3 | 5 |
| Incidence of study treatment-related TEAEs leading to withdrawal of study treatment | 1 | 1 | 3 | 5 |
| Incidence of TESAEs | 6 | 4 | 4 | 4 |
| Incidence of study treatment-related TESAEs | 1 | 1 | 0 | 0 |
| Incidence of TEAEs leading to death | 0 | 0 | 1 | 1 |
| Incidence of study treatment-related TEAEs leading to death | 0 | 0 | 0 | 0 |
A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment.
| Participants | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High |
|---|---|---|---|---|
| Incidence of TEAEs | 21 | 22 | 21 | 21 |
| Mild | 7 | 9 | 12 | 6 |
| Moderate | 9 | 9 | 4 | 14 |
| Severe | 5 | 4 | 5 | 1 |
A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment. A TEAE was considered study treatment-related if there was a reasonable causal relationship between study intervention administration and the TEAE.
| Participants | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High |
|---|---|---|---|---|
| Incidence of Study Treatment-related TEAEs | 7 | 5 | 6 | 11 |
| Mild | 4 | 4 | 3 | 4 |
| Moderate | 2 | 0 | 2 | 7 |
| Severe | 1 | 1 | 1 | 0 |
Descriptive summary statistics were calculated for ONO-2808 plasma concentrations, by dose level and time point.
| ng/mL | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High |
|---|---|---|---|
| Week 2 (Before Daily Dose) | 186.6 ± 63.6 | 378.2 ± 129.1 | 612.7 ± 176.0 |
| Week 8 (Before Daily Dose) | 207.9 ± 69.5 | 396.4 ± 117.7 | 780.0 ± 231.6 |
| Week 12 (Before Daily Dose) | 202.4 ± 67.2 | 409.4 ± 108.2 | 851.4 ± 343.4 |
| Week 12 (3h ± 1h Post Daily Dose) | 264.6 ± 86.3 | 474.8 ± 118.4 | 1093.3 ± 373.4 |
| Week 12 (5h ± 1h Post Daily Dose) | 267.1 ± 91.2 | 492.3 ± 119.7 | 1201.2 ± 321.9 |
| Week 24 (Before Daily Dose) | 220.0 ± 69.8 | 395.0 ± 145.1 | 778.9 ± 406.9 |
| Week 24 (3h ± 1h Post Daily Dose) | 286.6 ± 89.7 | 540.7 ± 152.5 | 1158.9 ± 326.0 |
| Week 24 (5h ± 1h Post Daily Dose) | 284.8 ± 85.8 | 556.4 ± 163.1 | 1116.2 ± 330.7 |
Collected over From screening up to follow-up for the core part (up to Week 28). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/23 (0%) | 6/23 (26.1%) | 21/23 (91.3%) |
| ONO-2808 Low | 0/23 (0%) | 4/23 (17.4%) | 22/23 (95.7%) |
| ONO-2808 Middle | 1/23 (4.3%) | 4/23 (17.4%) | 21/23 (91.3%) |
| ONO-2808 High | 1/23 (4.3%) | 4/23 (17.4%) | 21/23 (91.3%) |
| Event | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/23 | 0/23 | 0/23 | 1/23 |
| BronchitisInfections and infestations | 0/23 | 0/23 | 1/23 | 0/23 |
| PneumoniaInfections and infestations | 1/23 | 0/23 | 0/23 | 0/23 |
| Pneumonia aspirationInfections and infestations | 0/23 | 1/23 | 0/23 | 0/23 |
| Urinary tract infectionInfections and infestations | 0/23 | 0/23 | 1/23 | 0/23 |
| FallInjury, poisoning and procedural complications | 1/23 | 0/23 | 0/23 | 0/23 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/23 | 0/23 | 0/23 | 0/23 |
| Shoulder fractureInjury, poisoning and procedural complications | 0/23 | 1/23 | 0/23 | 0/23 |
| Blood creatine phosphokinase increasedInvestigations | 0/23 | 0/23 | 0/23 | 1/23 |
| Transaminases increasedInvestigations | 0/23 | 1/23 | 0/23 | 0/23 |
| Event | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 8/23 | 9/23 | 2/23 | 4/23 |
| HeadacheNervous system disorders | 0/23 | 3/23 | 2/23 | 6/23 |
| ConstipationGastrointestinal disorders | 0/23 | 1/23 | 0/23 | 4/23 |
| ContusionInjury, poisoning and procedural complications | 4/23 | 2/23 | 1/23 | 1/23 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/23 | 1/23 | 1/23 | 1/23 |
| FallInjury, poisoning and procedural complications | 3/23 | 3/23 | 2/23 | 0/23 |
| NasopharyngitisInfections and infestations | 1/23 | 0/23 | 2/23 | 3/23 |
| FatigueGeneral disorders | 3/23 | 1/23 | 1/23 | 2/23 |
| DizzinessNervous system disorders | 1/23 | 0/23 | 0/23 | 3/23 |
| DiarrhoeaGastrointestinal disorders | 3/23 | 1/23 | 1/23 | 0/23 |
| Age, Continuous(years) | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High | Total |
|---|---|---|---|---|---|
| Median | 58.0 (51 to 76) | 63.0 (46 to 80) | 65.0 (54 to 74) | 60.0 (49 to 73) | 62.0 (46 to 80) |
| Age, Customized(Participants) | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High | Total |
|---|---|---|---|---|---|
| 30-<50 years | 0 | 1 | 0 | 1 | 2 |
| 50-<65 years | 18 | 14 | 10 | 14 | 56 |
| 65-<75 years | 4 | 6 | 13 | 8 | 31 |
| >=75 years | 1 | 2 | 0 | 0 | 3 |
| Sex: Female, Male(Participants) | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High | Total |
|---|---|---|---|---|---|
| Female | 8 | 14 | 9 | 10 | 41 |
| Male | 15 | 9 | 14 | 13 | 51 |
| Race (NIH/OMB)(Participants) | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 7 | 3 | 9 | 6 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 1 | 2 | 5 |
| White | 15 | 18 | 13 | 15 | 61 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High | Total |
|---|---|---|---|---|---|
| United States | 19 | 21 | 15 | 20 | 75 |
| Japan | 4 | 2 | 8 | 3 | 17 |
| Years since Initial Diagnosis of Primary Disease(Participants) | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High | Total |
|---|---|---|---|---|---|
| 0-<1 year | 8 | 6 | 10 | 8 | 32 |
| 1-<2 years | 10 | 10 | 6 | 9 | 35 |
| 2-<3 years | 3 | 4 | 3 | 2 | 12 |
| 3-<4 years | 2 | 2 | 3 | 3 | 10 |
| 4-<5 years | 0 | 1 | 1 | 1 | 3 |
| Subtype of multiple system atrophy (MSA)(Participants) | Placebo | ONO-2808 Low | ONO-2808 Middle | ONO-2808 High | Total |
|---|---|---|---|---|---|
| Likely MSA-P (Parkinsonian subtype of MSA) | 13 | 11 | 12 | 12 | 48 |
| Likely MSA-C (Cerebellar subtype of MSA) | 10 | 12 | 11 | 11 | 44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2023 to primary completion in Sep 2025, 23 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 19 phase 2 interventional studies under Multiple System Atrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 32. This study's 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ONO-2808
Ono Pharmaceutical Co., Ltd. →